STM2457 is primarily used as a potent and selective inhibitor of the METTL3-METTL14 methyltransferase complex, which plays a key role in RNA methylation, specifically N6-methyladenosine (m6A) modification. This compound is widely applied in epigenetic research to modulate m6A levels in cellular RNA, enabling scientists to study the functional impact of this modification on gene expression, RNA stability, splicing, and translation. In cancer research, STM2457 has shown promise in preclinical studies by suppressing the growth of certain leukemia and solid tumor cells where dysregulated m6A methylation contributes to oncogenesis. By inhibiting METTL3, STM2457 can reactivate tumor suppressor pathways and induce differentiation or apoptosis in malignant cells. Additionally, STM2457 serves as a valuable tool compound in target validation studies for drug discovery, helping to assess the therapeutic potential of targeting the m6A methylation pathway. Its application extends to studying developmental biology, immune responses, and neurological functions where RNA methylation is implicated.